Estrella Immunopharma, Inc. SEC filings ESLA
Estrella Immunopharma, Inc. has 258 filings in SEC EDGAR's recent list, going back to Feb 19, 2021. Its latest annual report, Form 10-K, was filed on Mar 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 10-Q | Notification of late filing | May 18, 2026 | Mar 31, 2026 |
| EFFECT | Filing | Jan 23, 2026 | — |
| CORRESP | Letter to the SEC | Jan 22, 2026 | — |
| UPLOAD | Letter from the SEC | Dec 29, 2025 | — |
| EFFECT | Filing | Dec 19, 2024 | — |
| CORRESP | Letter to the SEC | Dec 17, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 17, 2024 | — |
| EFFECT | Filing | Dec 28, 2023 | — |
| CORRESP | Letter to the SEC | Dec 27, 2023 | — |
| CORRESP | Letter to the SEC | Dec 15, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2023 | — |
| NT 10-Q | Notification of late filing | Nov 15, 2023 | Sep 30, 2023 |
| CORRESP | Letter to the SEC | Nov 13, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 23, 2023 | — |
| 25-NSE | Delisting notice | Oct 5, 2023 | — |
| 425 | Current report | Sep 20, 2023 | — |
| 425 | Current report | Sep 18, 2023 | — |
| 425 | Current report | Aug 18, 2023 | — |
| 425 | Current report | Aug 1, 2023 | — |
| 425 | Current report | Jul 26, 2023 | — |
| 425 | Current report | Jul 19, 2023 | — |
| SEC STAFF LETTER | Filing | Jul 18, 2023 | — |
| EFFECT | Filing | Jul 11, 2023 | — |
| CORRESP | Letter to the SEC | Jul 6, 2023 | — |
| CORRESP | Letter to the SEC | Jun 30, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 26, 2023 | — |
| 425 | Form 425 | Jun 21, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2023 | — |
| CORRESP | Letter to the SEC | Jun 15, 2023 | — |
| PRER14A | Prer 14a | Jun 2, 2023 | — |
| 425 | Form 425 | May 19, 2023 | — |
| UPLOAD | Letter from the SEC | May 17, 2023 | — |
| NT 10-Q | Form nt 10-q | May 16, 2023 | May 15, 2023 |
| SEC STAFF LETTER | Filing | May 9, 2023 | — |
| CORRESP | Letter to the SEC | May 1, 2023 | — |
| 425 | Form 425 | Apr 26, 2023 | — |
| 425 | Form 425 | Apr 24, 2023 | — |
| 425 | Form 425 | Apr 13, 2023 | — |
| 425 | Form 425 | Mar 20, 2023 | — |
| 425 | Form 425 | Mar 8, 2023 | — |
| 425 | Form 425 | Feb 21, 2023 | — |
| SEC STAFF LETTER | Filing | Feb 17, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 17, 2023 | — |
| 425 | Filing | Jan 24, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 29, 2022 | — |
| CORRESP | Letter to the SEC | Dec 16, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 7, 2022 | — |
| PRER14A | Filing | Dec 2, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2022 | — |
| CERT | Filing | Jul 15, 2021 | — |
| EFFECT | Filing | Jul 14, 2021 | — |
| 8-A12B | Filing | Jul 14, 2021 | — |
| CORRESP | Letter to the SEC | Jul 13, 2021 | — |
| CORRESP | Letter to the SEC | Jul 13, 2021 | — |
| CORRESP | Letter to the SEC | Jul 9, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2021 | — |
| CORRESP | Letter to the SEC | Jun 24, 2021 | — |
| CORRESP | Letter to the SEC | Jun 24, 2021 | — |
| CORRESP | Letter to the SEC | Jun 22, 2021 | — |
| CORRESP | Letter to the SEC | Jun 22, 2021 | — |
| CORRESP | Letter to the SEC | Jun 11, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2021 | — |
| CORRESP | Letter to the SEC | May 28, 2021 | — |
| UPLOAD | Letter from the SEC | May 27, 2021 | — |
| CORRESP | Letter to the SEC | May 18, 2021 | — |
| UPLOAD | Letter from the SEC | May 17, 2021 | — |
| CORRESP | Letter to the SEC | Apr 9, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 9, 2021 | — |
| CORRESP | Letter to the SEC | Mar 26, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 18, 2021 | — |
Showing 70 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ESLA (Nasdaq), ESLAW (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1844417
- Former names
- TradeUP Acquisition Corp. (until Sep 20, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.